Skip to content

Seroprevalence of Covid-19 in the Staff of the University Hospitals of Strasbourg

Seroprevalence of SARS-CoV 2 in the Staff of the University Hospitals of Strasbourg

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05652582
Acronym
SeroPrevHUS
Enrollment
5694
Registered
2022-12-15
Start date
2021-06-24
Completion date
2022-06-24
Last updated
2023-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, SARS-COV-2, Prevalence of SARS-CoV-2

Brief summary

The Grand Est region is one of the most affected regions in France during the first wave of the COVID-19 epidemic. A significant increase in the number of patients hospitalized for SARS-CoV 2 infection at the University Hospitals of Strasbourg (HUS) led to a sudden saturation of their capacities. Hospital workers appear to be a population at particular risk for this new infectious agent. The percentage of hospital workers who have been in contact with the virus or have contracted COVID-19 is unknown. The objective of this work is to determine the prevalence of SARS-CoV-2 positive serologies among hospital staff screened from June 22, 2020 to November 1, 2020 following a screening campaign offering serological testing to all volunteer HUS professionals.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adult subject (≥ 18 years of age) * Hospital staff practicing at HUS who performed SARS-CoV 2 serology in the period from 06/22/2020 to 11/1/2020

Exclusion criteria

\- Subject not meeting inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
To determine the positive seroprevalence of SARS-CoV-2 among hospital staff screened from June 22, 2020 to November 1, 2020Files analysed retrospectively from June 22, 2020 to November 1, 2020 will be examinedSeroprevalence will be estimated by calculating the rate of seropositive subjects with its 95% confidence interval

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026